Breast Cancer - Selecting Adjuvant Therapy
Managing breast cancer across the continuum of care, including early breast cancer, metastatic disease, and survivorship is a complex and rapidly evolving task. Clinical trials have pointed to new strategies in managing local disease, using surgery, radiation therapy, and systemic therapy to achieve the best possible outcomes. Similarly, for patients with advanced disease, clinical trials have pointed to management based on tumor biology. Additionally, clinicians use individual patient characteristics, adverse event profiles of regimens, and patient preference to select the most effective and tolerable treatment strategy for the individual. Healthcare providers in survivorship clinics and primary care physicians should be aware of the recommendations in the new NCCN Guidelines for Survivorship Care to ensure optimal care for patients who have completed active treatment. Such care will improve the quality of life for survivors and likely increase their compliance with surveillance and risk-reduction recommendations.
This educational activity is designed to meet the needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Discuss the use of adjuvant endocrine therapy, chemotherapy, and targeted therapy based on risk of recurrence for early stage breast cancer according to the tumor’s biology
John H. Ward, MD
Huntsman Cancer Institute at the University of Utah
- 0.25 Participation
- 0.21 Nurse
- 0.25 Pharmacist
- 0.25 Physician